Johnson & Johnson has announced a major breakthrough in mental health treatment. The Food and Drug Administration (FDA) has approved Spravato, a novel nasal spray, for the standalone treatment of ...

Bipolar disorder is a complex psychiatric disorder, characterized by fluctuations between episodes of (hypo)mania and ...

The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...

Antipsychotic medications can help a person with bipolar disorder stabilize their moods, reduce agitation, and improve overall quality of life. Learn more about the medication types, dosage, side ...

Bipolar disorder is a mental health condition marked by extreme mood swings, ranging from manic highs to depressive lows, ...

The NIH recommends treating the mood disorder first until the patient is “stabilized.” Stabilized is the key word here, particularly if the patient is suicidal, manic, or psychotic. “If depression is ...

Lithium is a mood stabilizer used to treat bipolar disorder, a condition that involves episodes of depression, mania, and hypomania. Lithium is used as an acute treatment for mood episodes and as a ...

Older adults with major depressive disorder (MDD) demonstrate distinct and riskier driving behaviors than those without MDD, according to a study published online Dec. 30 in JAMA Network Open.

JNJ-18038683 is under clinical development by Johnson & Johnson and currently in Phase II for Bipolar Disorder (Manic Depression). According to GlobalData, Phase II drugs for Bipolar Disorder (Manic ...

People with bipolar disorder often have irregular biological clocks, leading to erratic sleep-wake cycles. Lack of sleep can trigger manic episodes. Excessive sleep or irregular patterns can ...